Multiplikator Forward P/S: RXi Pharmaceuticals (PHIO)
Phio Pharmaceuticals (PHIO) maintains its pioneer status in developing INTASYL self-delivering RNA therapies for tumor combat. Current portfolio diversification through gene silencing in skin and organ tissues complements this foundation. Stable laboratory operations ensure research continuity. The company's expected P/S ratio demonstrates a balance between these factors, while the metric reflects the current dynamics of alignment between market valuation and margin forecasts.
Rincian metrik lan analitis perusahaan phiopharma.com (PHIO)
- rega pasar lan target rega analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Phio Pharmaceuticals|PHIO - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Phio Pharmaceuticals Corp.|PHIO - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku PHIO|PHIO - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Phio Pharmaceuticals|Rasio cepet phiopharma.com
- rincian asil keuangan lan kelipatan valuasi:
PHIO - Bathi resik|Bathi sing dikarepake Phio Pharmaceuticals|PHIO - Rasio rega marang bathi|Rega marang bathi mangsa ngarep Phio Pharmaceuticals Corp.|PHIO - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PHIO|PHIO - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Phio Pharmaceuticals|PHIO - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan phiopharma.com|PHIO - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Phio Pharmaceuticals
- data dodolan lan asil:
Analisis umum perusahaan:RXi Pharmaceuticals PHIO
Analyzing the current forward P/S ratio allows for an assessment of the market value of Phio Pharmaceuticals (PHIO) relative to expected revenues from the implementation of RNA technologies in immuno-oncology. This metric compares market capitalization with projected revenue, making it possible to determine the justification for the control premium over assets and evaluate the company's investment attractiveness in the context of seeking strategic partners to develop cancer treatment programs.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|QGEN - Multiplikator forward rega marang pendapatan|Ionis Pharma - Multiplikator Forward P/S|RGEN - Multiplikator Forward P/S|RNA: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan crisprtx.com|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|Multiplikator Forward P/S Sarepta Corp (SRPT)|Twist Bioscience - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke Therapeutics Inc STOK|BLFS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Wave Pharma|MAZE (Maze Therapeutics Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S sionnatx.com|Rasio rega marang prakiraan pendapatan Prime Medicine (PRME)|Rasio rega marang prakiraan pendapatan TSHA (Taysha Gene Therapies Inc)|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|Rasio kapitalisasi marang dodolan sing dikarepake MeiraGTx Corp (MGTX)|RGNX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan SLDB|OCGN: Multiplikator Forward P/S|Pacific Biosciences of California, Inc. - Rega forward marang dodolan|BNTC (Benitec) - Multiplikator Forward P/S|Design Corp (DSGN) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|FDMT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S LXEO (Lexeo Therapeutics, Inc.)|KRRO: Kapitalisasi marang prakiraan pendapatan|EDIT - Rasio rega marang prakiraan pendapatan|SLN (Silence Therapeutics Corp) - Kapitalisasi marang prakiraan pendapatan|PRQR: Multiplikator Forward P/S|Codexis (CDXS) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Sangamo Therapeutics, Inc.|Nautilus Biotechnology Inc - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S MGX|DTIL (Precision BioSciences Inc.) - Rega forward marang dodolan|Multiplikator Forward P/S GBIO (Generation Bio)|Rasio kapitalisasi marang dodolan sing dikarepake boundlessbio.com (BOLD)|XCUR - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Imunon, Inc.|MBIO (mustangbio.com) - Multiplikator forward rega marang pendapatan|TransCode Therapeutics, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Bionano Genomics Inc.|adnas.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S BLUE|IPA (immunoprecise.com) - Rega forward marang dodolan|Multiplikator Forward P/S OMGA (Omega)|Multiplikator Forward P/S Singular Genomics Corp OMIC|RGLS - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan SYRS (syros.com)|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan TRACON Pharmaceuticals Inc.|UBX (Unity Bio) - Multiplikator Forward P/S
